Rheumatoid Arthritis | Unmet Need | US/EU | 2016

launch Related Market Assessment Reports

• Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast

  November 2023

  Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-…

• Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Detailed, Expanded Analysis (US)

  November 2023

  CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Janssen’s Carvykti, have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and patients…

• Attention-Deficit-Hyperactivity Disorder – Access & Reimbursement – Detailed, Expanded Analysis (US)

  November 2023

  Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist through adolescence and into adulthood, although diagnosis and treatment initiation can occur at…

• Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

  October 2023

  Depressive episodes are more common than manic episodes in bipolar disorder (BPD) patients. Of note, BPD II is often characterized by a higher frequency of depressive episodes that last longer…

• Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

  Depressive episodes are more common than manic episodes in bipolar disorder (BPD) patients. Of note, BPD II is often characterized by a higher frequency of depressive episodes that last longer…